Is there a contradiction between profit-making and medical needs? How important are emerging markets for the future of pharmaceutical companies? And what are the ethical boundaries in the relationship between medical practitioners and pharma companies?

*Addicted to Big Pharma?* brings together leading figures in the pharmaceutical industry, health and business to look at the challenges of reconciling medical ethics and business in the 21st century against a backdrop of scientific and clinical developments and the expectations of patients.

The lectures

**Tuesday 5 May**

*The origin and evolution of the pharmaceutical industry*

Speaker: Tilli Tansey, Professor of History of Modern Medical Sciences, University College London

**Tuesday 12 May**

*Pharmaceutical companies, government and society*

Speaker: Sir Michael Rawlins, Chairman, National Institute of Health and Clinical Excellence

Respondent: Chris Brinsmead, President of the Association of the British Pharmaceutical Industry (ABPI)

**Tuesday 2 June**

*A Pharma perspective on healthcare needs and innovation in drug discovery*

Speaker: Patrick Vallance, head of drug discovery, GlaxoSmithKline

Respondent Philip Bloomer, Director of Campaigns and Policy, Oxfam

**Tuesday 9 June**

*Is there a healthy future for Big Pharma?*

Speaker: Dr John Patterson, former Executive Director, Development, AstraZeneca

Respondent: Sophia Tickell, Director, PharmaFutures

All lectures take place at 6pm in the Nissan Lecture Theatre in St Anthony’s College

**Green Templeton College**

Green Templeton – Oxford University’s newest graduate college – is perfectly placed to explore these themes. With a distinctive intellectual and academic agenda broadly centred on human welfare and directly concerned with the contemporary world, its expertise spans both medicine and management studies. The overlap between medical and management sciences or the ‘business of health’, offers the chance to focus on the future of healthcare and medicine and their delivery, management and organization and to link scholarship with the professions, practice and policy.
The speakers

Tilli Tansey, Professor of the history of modern medical sciences at the Wellcome Trust Centre for the History of Medicine, University College London

Tilli has published extensively in both historical and medical journals, specializing in physiology, neurosciences and pharmacology, and has also published on medical research and the pharmaceutical industry. She is currently writing a book on medical laboratory technicians. She is the only medical historian who is a Fellow of the Academy of Medical Sciences, only the second to have been elected (the first being the late Roy Porter), and was elected an Honorary Fellow of the Royal College of Physicians of London in 2008.

Sir Michael Rawlins, Chairman, National Institute of Health and Clinical Excellence

Sir Michael Rawlins has been chairman of NICE since its formation in 1999. He was until recently also chairman of the Advisory Council on the Misuse of Drugs (1998-2008). He is an Honorary Professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne. He was the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at the University of Newcastle upon Tyne from 1973 to 2006. At the same time he held the position of consultant physician and consultant clinical pharmacologist to the Newcastle Hospitals NHS Trust. He was vice-chairman (1987-1992) and chairman (1993-1998) of the Committee on Safety of Medicines.

Chris Brinsmead, President ABPI

Chris has worked in the pharmaceutical industry with AstraZeneca since 1980 in local commercial roles in the UK and Canada, internationally on global commercial development of a portfolio of cancer medicines, regional management in Asia and as leader of a global techno-commercial group. He was appointed Vice President Global Marketing in 1999, President of AstraZeneca UK in January 2002 and President of the ABPI in April 2008. He is Chairman of a UKTI Life Sciences Board set up to market the UK as a base for trade and investment in life sciences, co-chairs a Ministerial Industry Strategy Group [MISG] Research and Development committee with the Department of Health and chairs AZ’s UK Pharma business.

John Patterson, former Executive Director, Development, AstraZeneca

John’s R&D career with ICI Pharmaceuticals spanned 18 years. He joined the Pharmaceuticals Business Board as Medical Director in 1990, having held senior roles in the UK, USA and Germany. In 1994, he joined Zeneca European and, following the AstraZeneca merger, became responsible for global marketing for all brands, including the management of the AstraZeneca product portfolio, licensing and business development. In 2004 he was appointed to the main Board as Executive Director responsible for Development of all AstraZeneca’s new medicines. He retired from AstraZeneca in March 2009. John is a Fellow of the Academy of Medical Sciences and former President of the Association of the British Pharmaceutical Industry.

Patrick Vallance, Head of Drug Discovery, GlaxoSmithKline

Patrick oversees that part of the pipeline that runs from the initial chemical hit against a target through developing the medicine and testing it to ‘proof of concept’ in the clinic. Prior to joining GSK in May 2006 he was a clinical academic and led the Division of Medicine at UCL. He has an international reputation as a vascular biologist and clinician scientist. His research has been translational, spanning structural and molecular studies, in vitro and in vivo experimental pharmacology and clinical studies including the use of large scale patient databases. He was elected to the Academy of Medical Sciences in 1999 and was Registrar of the Academy up to the time he moved to GSK.

Sophia Tickell, Director, Pharma Futures

An historian, Sophia spent fifteen years working on international development issues in India, Zambia, and Colombia, and in policy, most recently as Oxfam Great Britain’s Senior Policy Advisor on the private sector. She is the Chairperson of SustainAbility, the award-winning, independent think tank and strategy consultancy which for 20 years has worked with business to contribute to a world that future generations want to inherit. Sophia is the author of a number of publications, including The Antibiotic Innovation Study and Pharma Futures: Prescription for Long Term Value. Sophia is a member of the European Healthcare Innovation Leadership Network and is an alumnus of Al Gore’s Climate Project.